home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

353.93 +5.50 (+1.58%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

64 65 Next >

IBM, Verizon, Merck stocks lead Dow to new highs

January 31, 2024

The Dow hits record highs with IBM, Verizon, Merck, and insurer Travelers leading the way; those strong stocks don't make much of a dent in S&P performance

Via MarketBeat

Topics Stocks

Is Amgen a Good Dividend Stock to Buy Right Now? ↗

January 29, 2024

Its diverse product mix and strong fundamentals make a decent case.

Via The Motley Fool

Amgen's Planning to Take a Bite Out of Cancer. Here's What It Means for the Stock. ↗

January 27, 2024

Its new approach to treating cancer is more than just a nibble around the edges.

Via The Motley Fool

Should You Buy the Dogs of the Dow in 2024? ↗

January 27, 2024

Via The Motley Fool

Topics Stocks

P/E Ratio Insights for Amgen ↗

January 26, 2024

Via Benzinga

Amgen Options Trading: A Deep Dive into Market Sentiment ↗

January 17, 2024

Via Benzinga

Why NASDAQ:AMGN is a Top Pick for Dividend Investors. ↗

January 12, 2024

Balancing Dividends and Fundamentals: The Case of AMGEN INC (NASDAQ:AMGN).

Via Chartmill

Earnings Scheduled For February 6, 2024 ↗

February 06, 2024

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.

Via Benzinga

3 Fantastic Dow Stocks to Buy in February 2024 ↗

February 05, 2024

The venerable index is more representative of today's economy and these three Dow stocks to buy are brightly shining component stars.

Via InvestorPlace

Topics Economy Stocks

NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment? ↗

February 05, 2024

The relaunch of Wegovy last year caused a mad dash by weight loss stocks to compete for market leadership in anti-obesity drugs.

Via InvestorPlace

Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record ↗

February 05, 2024

Amgen is looking to rival Eli Lilly and Novo Nordisk in weight-loss drugs.

Via Investor's Business Daily

Weight Loss Drug's New Entrant: Amgen To Compete With Novo Nordisk, Eli Lilly, As Investigational Weight Loss Drug Shows Encouraging Early Data ↗

February 05, 2024

Amgen's AMG 133 data. Promising results in obesity drug trials, including significant weight loss and improved metabolic markers.

Via Benzinga

Preview: Amgen's Earnings ↗

February 05, 2024

Via Benzinga

Is Amgen Stock a Buy Now? ↗

February 01, 2024

The biotech has an excellent track record, but that isn't enough to make its shares attractive.

Via The Motley Fool

Amgen Options Trading: A Deep Dive into Market Sentiment ↗

January 30, 2024

Via Benzinga

Expert Outlook: Amgen Through The Eyes Of 11 Analysts ↗

January 29, 2024

Via Benzinga

5 top healthcare stocks for earnings growth in 2024

January 25, 2024

2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.

Via MarketBeat

ABBV: This Top Biotech Just Went On A Buying Spree ↗

January 25, 2024

AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel).

Via Talk Markets

Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs ↗

January 25, 2024

The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments.

Via InvestorPlace

What's Going On Johnson & Johnson Stock Today? ↗

January 24, 2024

JNJ reports strong earnings, beats expectations for Q4 of 2023, with increased sales and successful acquisitions. Stock closes lower, settles talc litigation, and delays competitor's launch.

Via Benzinga

Topics Earnings

This 1 Bullish Move by Merck Could Drive Growth for Years to Come ↗

January 23, 2024

It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually.

Via The Motley Fool

5 Magnificent Dividend Growth Stocks to Buy and Hold Forever ↗

January 23, 2024

These dividend growers ought to shine in 2024 and beyond.

Via The Motley Fool

Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning ↗

January 19, 2024

FDA issues serious warning on Amgen's Prolia drug, highlighting increased risk of low calcium levels in specific patient groups.

Via Benzinga

Dividend Income Update December 2023 ↗

January 17, 2024

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated.

Via Talk Markets

Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units ↗

January 16, 2024

On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units.

Via Benzinga

Topics ETFs

Stocks Struggle As U.S. Dollar Sees Safety Bid ↗

January 16, 2024

Once again, we are seeing stocks struggle whenever the dollar catches a bid. But not all hope is lost for bulls, as various semiconductor stocks continue to hold up well.

Via Talk Markets

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 15, 2024

Via Benzinga

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond ↗

January 15, 2024

These five biotech companies could have a lot of room to run.

Via The Motley Fool

Why Vera Therapeutics Stock Soared by 22% This Week ↗

January 12, 2024

Executive changes and a bullish analyst take combined to boost sentiment on the company.

Via The Motley Fool

Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance ↗

January 11, 2024

Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the

Via Benzinga

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

64 65 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com